Company / Free Cash Flow
Axsome Therapeutics, Inc. Free Cash Flow History
FY2016-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Free Cash Flow
-$93.9M
FY2025
5-year range
-$145.7M / -$93.9M
FY2021-FY2025
Trend
+27.0%
vs FY2024
Sector context
#106 of 194
Health Care
What the data says
At -$94M, Axsome Therapeutics, Inc.'s free cash flow ranks #106 of 194 in the Health Care sector. Improved from -$146M to -$94M over the past 2 years.
Based on SEC 10-K filings.
-$94M in FY2025.
Improved from -$146M to -$94M over the past 2 years.
Health Care sector context is included.
Free Cash Flow over time
Growth rates
- 3-Year CAGR
- -
- 5-Year CAGR
- -
- 10-Year CAGR
- -
Sector benchmark
#106 of 194 in Health CareTop 55% of 194This company -$93.9M Sector average $470.6M
▼
-120.0% below sector average
Key checks
Key Insights
- In FY2025, free cash flow increased 27.0% year-over-year.
- Ranks #106 out of 194 companies in the Health Care sector.
- Peak free cash flow was recorded in FY2016.
- Lowest free cash flow in the period was in FY2023.
Company context
Key Data Points
- Altman Z-Score -1.15 (distress zone, below 1.8 threshold)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Free Cash FlowValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | -$93.9M | +27.0% |
| FY2024 | -$128.7M | +11.7% |
| FY2023 | -$145.7M | -24.3% |
| FY2022 | -$117.2M | -8.0% |
| FY2021 | -$108.5M | -38.3% |
| FY2020 | -$78.5M | -69.2% |
| FY2019 | -$46.4M | -54.2% |
| FY2018 | -$30.1M | -13.6% |
| FY2017 | -$26.5M | -23.8% |
| FY2016 | -$21.4M | -186.7% |
As of FY2025 · SEC 10-K · Updated Feb 28, 2026